PRINCETON, N.J., April 4 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, announced today that Leslie J. Browne, Ph.D., President and Chief Executive Officer, will chair a panel of industry leaders at BIO 2006 in Chicago entitled, “Fast Forward: Building Company Value through Forward Integration.” The panel will address the trend toward forward integration within the biotech industry, as well as the risks and rewards associated with such innovation.
Date and Time: Monday, April 10, 2006, 4:00 PM Location: McCormick Place, Room 426B, North Building Track: Emerging Company Issues Moderator/Chair: Leslie J. Browne, Ph.D., President & CEO Pharmacopeia Drug Discovery, Inc. Panelists: -- Fred Craves, Co-Founder & Managing Director, Bay City Capital -- Alan J. Lewis, Ph.D., President & Chief Executive Officer, Novocell, Inc. -- Mats Pettersson, CEO, Biovitrum AB -- Arthur T. Sands, M.D., Ph.D., President, CEO & Director, Lexicon Genetics, Inc. Panel Description: Fast Forward: Building Company Value through Forward Integration A recent trend in the biotech industry is to forward integrate by in-licensing compounds in clinical development. The driver is clearly that the capital markets place an emphasis on significant ownership of clinical assets, and ideally compounds for which clinical proof-of-concept has been achieved, when valuing biotechnology companies, be they private or public. This creates some critical dilemmas and paradoxes in the industry that this panel discussion will explore. For example, is the trend sustainable? Is the trend forcing biotech companies to compete head to head with Big Pharma? How will the industry reward the risks of innovation? ABOUT PHARMACOPEIA
Pharmacopeia is committed to creating and delivering novel therapeutics to address significant medical needs using proprietary technologies and processes. The Company is advancing multiple internal programs towards validation in clinical trials. Pharmacopeia’s later stage portfolio currently comprises multiple partnered programs that have been advanced into clinical trials with further programs in late-stage preclinical development. The Company also has several internal programs in advanced preclinical optimization and multiple partnered programs in discovery that are expected to drive the Company’s clinical portfolio in the future.
Contact: Michio Soga Executive Vice President and Chief Financial Officer Pharmacopeia (609) 452-3643 irreq@pcop.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia’s strategic plans, Pharmacopeia’s plans to develop its DARA program, Pharmacopeia’s ability to build its pipeline of novel drug candidates, through in-licensing, its own internally-funded drug discovery programs and third party collaborations, Pharmacopeia’s ability to successfully perform under its new collaboration with GlaxoSmithKline, the planned cessation of full-time employee funding from Pharmacopeia’s existing collaborations with Schering-Plough, the continuation and funding level of such continuation of Pharmacopeia’s existing drug discovery collaboration with N.V. Organon, Pharmacopeia’s intentions regarding the establishment of new drug discovery collaborations with leading pharmaceutical and biotechnology organizations, Pharmacopeia’s expectations concerning the development priorities of its collaborators and their ability to successfully develop compounds, Pharmacopeia’s ability to raise additional capital, Pharmacopeia’s anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia’s expectations concerning the legal protections afforded by U.S. and international patent law, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its Report on Form 10-K filed on March 20, 2006 and subsequent filings under the Securities and Exchange Act of 1934. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Pharmacopeia
CONTACT: Michio Soga, Executive Vice President and Chief FinancialOfficer, Pharmacopeia, +1-609-452-3643, irreq@pcop.com
Web site: http://www.pharmacopeia.com/
